AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Somewhat Bullish +40

AbbVie Inc. Just Missed Earnings - But Analysts Have Updated Their Models

📉 AbbVie's quarterly statutory earnings per share fell sharply, missing estimates by 69% to reach US$0.39.

📈 Despite the earnings miss, the company's shares gained 4.0%, rising to US$207 on investor optimism.

💰 Revenue of US$15b came in exactly in line with analyst predictions for the latest quarter.

🔮 Analysts have updated their models to project 2026 revenues of US$67.4b, implying a 7.2% increase over the past 12 months.

⚡ Statutory earnings per share are predicted to surge by 318% to reach US$8.50 in 2026.

📊 The consensus price target remains largely unchanged at US$250 despite the recent results.

⚖️ There is a spread in analyst estimates with targets ranging from a low of US$184 to a high of US$294.

📉 AbbVie's forecast annualised revenue growth of 9.8% to 2026 is expected to significantly outpace its historical 5-year average of 2.0%.

⚠️ However, the company is still expected to grow meaningfully slower than the wider industry average, which is projected at 21% per year.

🧐 Overall sentiment remains stable as analysts have reconfirmed both earnings and revenue estimates for the future.

📈 Long-term analysis suggests the intrinsic value of the business has not undergone major changes with the latest data.

⚠️ A cautionary note indicates that AbbVie currently shows 5 warning signs in the investment analysis model.

Bullish Signals
  • AbbVie shares gained 4.0% to US$207 immediately following the release of its latest quarterly results.
  • The consensus forecast predicts that statutory earnings per share will jump 318% to US$8.50 by 2026.
  • Analyst estimates suggest a credible 7.2% revenue increase over the past 12 months, implying accelerated growth compared to the historical 2.0% annualised rate.
  • The consensus price target remained stable at US$250, indicating that analysts view the intrinsic value of the business as unchanged despite missing earnings.
  • Despite a miss in current statutory earnings, revenue came in line with analyst predictions at US$15 billion, demonstrating consistent top-line performance.
Risk Factors
  • Statutory earnings fell badly short, missing estimates by 69% to hit US$0.39 per share despite revenues being in line with predictions.
  • AbbVie is forecasted to grow revenue at 9.8% annually through 2026, which is significantly slower than the industry average of 21% per year.
  • Historical growth over the past five years has been merely 2.0% per annum, indicating long-term sluggishness compared to current acceleration.
  • Analyst sentiment remains split with a wide range in price targets, from US$184 for the most pessimistic view to US$294 for the most optimistic.
  • The company is identified as showing '5 warning signs' in its investment analysis framework.
  • No major change in analyst estimates following earnings suggests a lack of positive surprise despite the stock price gain.
Full Analysis
AbbVie Inc. (NYSE: ABBV) shareholders experienced a positive short-term reaction after the company released its latest quarterly results, with shares rising 4% to US$207. While revenues of US$15 billion matched analyst expectations, statutory earnings per share significantly missed forecasts, dropping by 69% to reach US$0.39. Despite this disappointing quarterly performance, investment sentiment remained largely unchanged, as analysts did not alter their long-term projections following the announcement. Looking beyond the current quarter, the consensus forecast from 27 analysts predicts AbbVie revenues will reach US$67.4 billion in 2026, representing a 7.2% increase over the previous year and a massive 318% jump in statutory EPS to US$8.50. These figures are nearly identical to pre-earnings models which had projected US$67.1 billion in revenue and US$8.65 per share, indicating that the missed earnings were viewed as an outlier rather than a trend shift. Consequently, the average price target remains stable at US$250, with individual analyst estimates ranging from a high of US$294 to a low of US$184. However, context regarding industry performance reveals that AbbVie is expected to grow more slowly than its peers. While the company anticipates an accelerated growth rate of 9.8% annually through 2026 compared to a historical average of 2.0% per year over the last five years, this still trails the broader industry average forecast of 21% annual revenue growth. Investors are reminded to focus on long-term earnings power extending into 2028 rather than short-term quarterly fluctuations, though analysis indicates AbbVie currently displays five warning signs that require attention despite the stable analyst consensus.